← Back to Clinical Trials
Recruiting NCT03810768

NCT03810768 Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03810768
Status Recruiting
Phase
Sponsor Technical University of Munich
Condition Metabolomics
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2022-09-02
Primary Completion 2026-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2022-09-02 with a primary completion date of 2026-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this mono-center pilot trial, surgical patients who are at high risk to be admitted to intensive care will be screened and asked for participation. We are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing. Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.

Eligibility Criteria

Inclusion Criteria: * invasive mechanically ventilated critically ill patient with expected intensive care unit stay \> 3 days * postoperative patient * ≥ 18 years old * American Society of Anesthesiology (ASA) classification ≥ III Exclusion Criteria: * moribund patient * non-curative care (comfort care)

Contact & Investigator

Central Contact

Stefan J Schaller, MD

✉ stefan.schaller@meduniwien.ac.at

📞 +4314040041020

Principal Investigator

Stefan J Schaller, MD

PRINCIPAL INVESTIGATOR

Technical University of Munich

Frequently Asked Questions

Who can join the NCT03810768 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Metabolomics. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03810768 currently recruiting?

Yes, NCT03810768 is actively recruiting participants. Contact the research team at stefan.schaller@meduniwien.ac.at for enrollment information.

Where is the NCT03810768 trial being conducted?

This trial is being conducted at Vienna, Austria, Munich, Germany, Berlin, Germany.

Who is sponsoring the NCT03810768 clinical trial?

NCT03810768 is sponsored by Technical University of Munich. The principal investigator is Stefan J Schaller, MD at Technical University of Munich. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology